|
|
|
Volumn 55, Issue 1407, 2013, Pages 1-3
|
|
Tofacitinib (Xeljanz) for rheumatoid arthritis
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABATACEPT;
ADALIMUMAB;
CERTOLIZUMAB PEGOL;
CORTICOSTEROID;
DISEASE MODIFYING ANTIRHEUMATIC DRUG;
ETANERCEPT;
FLUCONAZOLE;
GOLIMUMAB;
HYDROXYCHLOROQUINE;
HYDROXYCHLOROQUINE SULFATE;
INFLIXIMAB;
KETOCONAZOLE;
LEFLUNOMIDE;
METHOTREXATE;
MINOCYCLINE;
NONSTEROID ANTIINFLAMMATORY AGENT;
PLACEBO;
RIFAMPICIN;
RITUXIMAB;
SALAZOSULFAPYRIDINE;
TOCILIZUMAB;
TOFACITINIB;
TUMOR NECROSIS FACTOR INHIBITOR;
AMINOTRANSFERASE BLOOD LEVEL;
CHOLESTEROL BLOOD LEVEL;
DIARRHEA;
DIGESTIVE SYSTEM PERFORATION;
DRUG COST;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG MECHANISM;
DRUG RESPONSE;
FETUS RISK;
HEADACHE;
HUMAN;
HYPERTENSION;
LETTER;
LYMPHOMA;
MONOTHERAPY;
NONHUMAN;
OPPORTUNISTIC INFECTION;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RHEUMATOID ARTHRITIS;
RHINOPHARYNGITIS;
SIDE EFFECT;
SOLID TUMOR;
TERATOGENESIS;
TUBERCULOSIS;
UPPER RESPIRATORY TRACT INFECTION;
ANIMALS;
ARTHRITIS, RHEUMATOID;
HUMANS;
JANUS KINASE 3;
PYRIMIDINES;
PYRROLES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
|
|
EID: 84872029211
PISSN: 0025732X
EISSN: None
Source Type: Journal
DOI: None Document Type: Letter |
|
Times cited : (10)
|
|
References (5)
|
